Physician profile
Peter A Barba
NPI 1770647299
$1,699.66
in general payments reported to CMS, 2019-2025
20 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $154 · 2021: $19.09 · 2023: $130 · 2024: $365 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $271.34 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $250.48 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $188.10 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $177.27 | 2019-2025 | |
| Exact Sciences Corporation | $133.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $127.81 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $107.78 | 2019-2020 | |
| Corcept Therapeutics | $64.69 | 2024-2025 | Korlym |
| Axsome Therapeutics, INC. | $58.78 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $51.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.21 | 2019 | |
| Merck Sharp & Dohme LLC | $34.78 | 2019-2020 | |
| Biogen, INC. | $27.75 | 2024 | Spinraza |
| Circassia INC. | $22.69 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.90 | 2024 | |
| Alk-Abello, INC | $21.80 | 2025 | Odactra, Ragwitek, Grastek |
| Dexcom, INC. | $20.59 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $14.44 | 2019 | |
| Amarin Pharma, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Barba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.